Rolapitant is typically prescribed to cancer patients who are undergoing moderately to highly emetogenic chemotherapy. It is often used in combination with other antiemetic agents such as 5-HT3 antagonists and corticosteroids to provide comprehensive control of nausea and vomiting.
